Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Boughey, V. Suman, E. Mittendorf, G. Ahrendt, L. Wilke, B. Taback, A., Marilyn Leitch, H. Kuerer, Monet Bowling, T. Flippo-Morton, D. Byrd, D. Ollila, T. Julian, S. Mclaughlin, L. Mccall, W. Symmans, H. Le-Petross, B. Haffty, T. Buchholz, H. Nelson, K. Hunt (2013)
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.JAMA, 310 14
H. Kuerer, W. Yang, S. Krishnamurthy (2016)
Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'British Journal of Cancer, 114
N. Wolmark, Jiping Wang, E. Mamounas, J. Bryant, B. Fisher (2001)
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of the National Cancer Institute. Monographs, 30
K. Hunt, M. Yi, E. Mittendorf, C. Guerrero, G. Babiera, I. Bedrosian, R. Hwang, H. Kuerer, M. Ross, F. Meric-Bernstam (2009)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer PatientsAnnals of Surgery, 250
A. Robidoux, G. Tang, P. Rastogi, C. Geyer, C. Azar, J. Atkins, L. Fehrenbacher, H. Bear, L. Baez-Diaz, S. Sarwar, R. Margolese, W. Farrar, A. Brufsky, H. Shibata, H. Bandos, S. Paik, J. Costantino, S. Swain, E. Mamounas, N. Wolmark (2013)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.The Lancet. Oncology, 14 12
B. Fisher, Jong-Hyeon Jeong, S. Anderson, J. Bryant, E. Fisher, N. Wolmark (2002)
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.The New England journal of medicine, 347 8
B. Fisher, A. Brown, E. Mamounas, S. Wieand, A. Robidoux, R. Margolese, A. Cruz, Edwin Fisher, D. Wickerham, N. Wolmark, A. DeCillis, J. Hoehn, A. Lees, N. Dimitrov (1997)
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 7
M. Helvie, L. Joynt, R. Cody, L. Pierce, D. Adler, Sophia Merajver (1996)
Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.Radiology, 198 2
K. McGuire, Jorge Toro-Burguete, H. Dang, Jessica Young, A. Soran, M. Zuley, R. Bhargava, M. Bonaventura, Ronald Johnson, G. Ahrendt (2011)
MRI Staging After Neoadjuvant Chemotherapy for Breast Cancer: Does Tumor Biology Affect Accuracy?Annals of Surgical Oncology, 18
B. Lim (2015)
Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: Findings From The ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical TrialBreast Diseases: A Year Book Quarterly, 26
Y. Xing, M. Foy, D. Cox, H. Kuerer, K. Hunt, J. Cormier (2006)
Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancerBritish Journal of Surgery, 93
J. Baselga, I. Bradbury, H. Eidtmann, S. Cosimo, E. Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Dooren, G. Aktan, A. Goldhirsch, Tsai-Wang Chang, Z. Horváth, M. Coccia-Portugal, J. Dômont, L. Tseng, G. Kunz, J. Sohn, V. Semiglazov, G. Lerzo, M. Pálácova, V. Probachai, L. Pusztai, M. Untch, R. Gelber, M. Piccart-Gebhart (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 379
H. Umphrey, Bernreuter Wk, K. Bland, J. Carpenter, C. Falkson, A. Forero, K. Keene, H. Krontiras, R. Meredith, M. Urist, J. Santos (2012)
Abstract P3-03-03: A tri-modality imaging assessment algorithm to evaluate neoadjuvant therapy response in patients with operable breast cancerCancer Research, 72
J. Santos (2011)
Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?: Daveau C, Savignoni A, Abrous-Anane S, et al (Institut Curie, Paris, France) Int J Radiat Oncol Biol Phys 79:1452-1459, 2011 §Breast Diseases: A Year Book Quarterly, 22
E. Mamounas, S. Anderson, J. Dignam, H. Bear, T. Julian, C. Geyer, A. Taghian, D. Wickerham, N. Wolmark (2012)
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 32
N. Houssami, P. Macaskill, G. Minckwitz, M. Marinovich, E. Mamounas (2012)
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.European journal of cancer, 48 18
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 384
G. Minckwitz, A. Schneeweiss, S. Loibl, C. Salat, C. Denkert, M. Rezai, J. Blohmer, C. Jackisch, S. Paepke, B. Gerber, D. Zahm, S. Kümmel, H. Eidtmann, P. Klare, J. Huober, S. Costa, H. Tesch, C. Hanusch, J. Hilfrich, F. Khandan, P. Fasching, B. Sinn, K. Engels, K. Mehta, V. Nekljudova, M. Untch (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.The Lancet. Oncology, 15 7
J. Hage, C. Velde, J. Julien, M. Tubiana-Hulin, Cecile Vandervelden, L. Duchateau (2001)
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 22
M. Su (2013)
Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017Breast Diseases: A Year Book Quarterly, 24
A. Schneeweiss, S. Chia, T. Hickish, Vernon Harvey, A. Eniu, R. Hegg, C. Tausch, J. Seo, Y. Tsai, J. Ratnayake, V. Mcnally, G. Ross, J. Cortés (2013)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).Annals of oncology : official journal of the European Society for Medical Oncology, 24 9
R. Parra, H. Kuerer (2016)
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trialsBreast Cancer Research : BCR, 18
Armando Giuliano, K. Ballman, L. Mccall, P. Beitsch, Pat Whitworth, P. Blumencranz, A. Leitch, S. Saha, M. Morrow, Kelly Hunt (2016)
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized TrialAnnals of Surgery, 264
T. Kuehn, I. Bauerfeind, T. Fehm, B. Fleige, M. Hausschild, G. Helms, A. Lebeau, C. Liedtke, G. Minckwitz, V. Nekljudova, S. Schmatloch, P. Schrenk, A. Staebler, M. Untch (2013)
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.The Lancet. Oncology, 14 7
J. Santos, A. Cantor, K. Amos, A. Forero, M. Golshan, J. Horton, C. Hudis, N. Hylton, K. McGuire, F. Meric-Bernstam, I. Meszoely, R. Nanda, E. Hwang (2013)
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancerCancer, 119
C. Loo, M. Straver, S. Rodenhuis, S. Muller, J. Wesseling, M. Peeters, K. Gilhuijs (2011)
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 6
M. Marinovich, N. Houssami, P. Macaskill, F. Sardanelli, L. Irwig, E. Mamounas, G. Minckwitz, M. Brennan, S. Ciatto (2013)
Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.Journal of the National Cancer Institute, 105 5
C. Daveau, A. Savignoni, S. Abrous-Anane, J. Pierga, F. Reyal, C. Gautier, Y. Kirova, R. Dendale, F. Campana, A. Fourquet, M. Bollet (2011)
Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?International journal of radiation oncology, biology, physics, 79 5
A. Schott, M. Roubidoux, M. Helvie, D. Hayes, C. Kleer, L. Newman, L. Pierce, K. Griffith, S. Murray, K. Hunt, C. Paramagul, L. Baker (2005)
Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant ChemotherapyBreast Cancer Research and Treatment, 92
A. Ring, A. Webb, S. Ashley, W. Allum, S. Ebbs, G. Gui, N. Sacks, G. Walsh, I. Smith (2003)
Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 24
B. Clouth, S. Chandrasekharan, R. Inwang, Simon Smith, N. Davidson, P. Sauven (2006)
The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 33 8
T. King, M. Morrow (2015)
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapyNature Reviews Clinical Oncology, 12
A. Weiss, Katherine Lee, Y. Romero, Erin Ward, Yeunjeong Kim, H. Ojeda-Fournier, J. Einck, S. Blair (2014)
Calcifications on Mammogram Do Not Correlate with Tumor Size After Neoadjuvant ChemotherapyAnnals of Surgical Oncology, 21
H. Bear, S. Anderson, Roy Smith, C. Geyer, E. Mamounas, B. Fisher, A. Brown, A. Robidoux, R. Margolese, M. Kahlenberg, S. Paik, A. Soran, D. Wickerham, N. Wolmark (2006)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
C. Rudenstam, D. Zahrieh, J. Forbes, D. Crivellari, S. Holmberg, P. Rey, D. Dent, I. Campbell, J. Bernhard, K. Price, M. Castiglione‐Gertsch, A. Goldhirsch, R. Gelber, A. Coates (2006)
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
V. Dialani, T. Chadashvili, P. Slanetz (2015)
Role of Imaging in Neoadjuvant Therapy for Breast CancerAnnals of Surgical Oncology, 22
E. Mamounas (2015)
Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast CancerAnnals of Surgical Oncology, 22
M. Marinovich, F. Sardanelli, S. Ciatto, E. Mamounas, M. Brennan, P. Macaskill, L. Irwig, G. Minckwitz, N. Houssami (2012)
Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.Breast, 21 5
L. Dominici, Viviana Gonzalez, A. Buzdar, A. Lucci, E. Mittendorf, H. Le‐Petross, G. Babiera, F. Meric-Bernstam, K. Hunt, H. Kuerer (2010)
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancerCancer, 116
J. Classe, V. Bordes, L. Campion, H. Mignotte, F. Dravet, J. Levêque, C. Sagan, P. Dupré, G. Body, S. Giard (2009)
Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
R. Schulz-Wendtland (2012)
Neoadjuvant chemotherapy--monitoring: clinical examination, ultrasound, mammography, MRI, elastography: only one, only few or all?European journal of radiology, 81 Suppl 1
Randal Croshaw, Hilary Shapiro-Wright, E. Svensson, K. Erb, T. Julian (2011)
Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer PatientsAnnals of Surgical Oncology, 18
F. Peintinger, H. Kuerer, K. Anderson, J. Boughey, F. Meric-Bernstam, S. Singletary, K. Hunt, G. Whitman, T. Stephens, A. Buzdar, Marjorie Green, W. Symmans (2006)
Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant ChemotherapyAnnals of Surgical Oncology, 13
M. Jochelson, Katharine Lampen-Sachar, G. Gibbons, C. Dang, D. Lake, E. Morris, M. Morrow (2015)
Do MRI and Mammography Reliably Identify Candidates for Breast Conservation After Neoadjuvant Chemotherapy?Annals of Surgical Oncology, 22
T. Stephens (2011)
Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancerYearbook of Diagnostic Radiology, 2011
B. Adrada, L. Huo, D. Lane, E. Arribas, E. Resetkova, W. Yang (2015)
Histopathologic Correlation of Residual Mammographic Microcalcifications After Neoadjuvant Chemotherapy for Locally Advanced Breast CancerAnnals of Surgical Oncology, 22
O. Gentilini, U. Veronesi (2012)
Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND).Breast, 21 5
J. Boileau, B. Poirier, M. Basik, C. Holloway, L. Gaboury, L. Sidéris, S. Meterissian, A. Arnaout, M. Brackstone, D. McCready, S. Karp, I. Trop, A. Lisbona, F. Wright, R. Younan, L. Provencher, E. Patocskai, A. Omeroglu, A. Robidoux (2015)
Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 3
N. Hylton, J. Blume, W. Bernreuter, E. Pisano, M. Rosen, E. Morris, P. Weatherall, C. Lehman, G. Newstead, Sandra Polin, H. Marques, L. Esserman, M. Schnall (2012)
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.Radiology, 263 3
R. Alvarado, M. Yi, H. Le‐Petross, M. Gilcrease, E. Mittendorf, I. Bedrosian, R. Hwang, A. Caudle, G. Babiera, J. Akins, H. Kuerer, K. Hunt (2012)
The Role for Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy in Patients who Present with Node-Positive Breast CancerAnnals of Surgical Oncology, 19
E. Mamounas, A. Brown, S. Anderson, Roy Smith, T. Julian, B. Miller, H. Bear, C. Caldwell, A. Walker, W. Mikkelson, Jay Stauffer, A. Robidoux, Heather Theoret, Atilla Sovan, B. Fisher, D. Wickerham, N. Wolmark (2005)
Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 12
W. Sikov, D. Berry, C. Perou, Baljit Singh, C. Cirrincione, S. Tolaney, C. Kuzma, T. Pluard, G. Somlo, E. Port, M. Golshan, J. Bellon, D. Collyar, O. Hahn, L. Carey, C. Hudis, E. Winer (2015)
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 1
J. Heil, S. Kümmel, B. Schaefgen, S. Paepke, C. Thomssen, G. Rauch, B. Ataseven, R. Grosse, V. Dreesmann, T. Kühn, S. Loibl, J. Blohmer, G. Minckwitz (2015)
Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniquesBritish Journal of Cancer, 113
Sabine Huber, M. Wagner, I. Zuna, M. Medl, Heinrich Czembirek, Stefan Delorme (2000)
Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy.Anticancer research, 20 1B
L. Gianni, J. Baselga, W. Eiermann, V. Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Cussac, A. Bozhok, A. Martínez-agulló, M. Greco, M. Byakhov, J. López, M. Mansutti, P. Valagussa, G. Bonadonna (2009)
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15
Young-Seon Kim, J. Chang, H. Moon, Joongyub Lee, S. Shin, W. Moon (2016)
Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor SizeAnnals of Surgical Oncology, 23
S. Holmberg, D. Crivellari, D. Zahrieh, J. Forbes, P. Rey, D. Dent, P. Schaefer, J. Bernhard, I. Campbell, C. Rudenstam (2004)
A randomized trial comparing axillary clearance versus no axillary clearance in older patients (≥ 60 years) with breast cancer: First results of International Breast Cancer Study Group Trial 10-93.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
P. Rastogi, S. Anderson, H. Bear, C. Geyer, M. Kahlenberg, A. Robidoux, R. Margolese, J. Hoehn, V. Vogel, S. Dakhil, D. Tamkus, K. King, E. Pajon, Mary Wright, J. Robert, S. Paik, E. Mamounas, N. Wolmark (2008)
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 5
L. Mauriac, G. MacGrogan, A. Avril, M. Durand, A. Floquet, M. Debled, J. Dilhuydy, F. Bonichon (1999)
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS).Annals of oncology : official journal of the European Society for Medical Oncology, 10 1
Curr Breast Cancer Rep (2017) 9:148–155 DOI 10.1007/s12609-017-0242-y LOCAL-REGIONAL EVALUATION AND THERAPY (EP MAMOUNAS, SECTION EDITOR) Eliminating Surgery in Early-Stage Breast Cancer: Pipe-Dream or Worthy Consideration in Selected Patients? 1 2 1,3,4 Stephanie M. Wong & Jennifer De Los Santos & Mark Basik Published online: 22 April 2017 Springer Science+Business Media New York 2017 Abstract complete response following NST. The combination of mod- Purpose of Review Neoadjuvant systemic therapy (NST) has ern radiologic evaluation with image-guided tumour bed bi- become a valuable treatment approach for women with large opsies represents a potentially novel method towards selecting operable and locally advanced breast cancers by lessening the patients who could safely avoid surgical resection. extent of surgery required to adequately resect the primary Summary This article reviews the current evidence supporting tumour. As molecular subtyping has evolved, the develop- the elimination of surgery in selected patients, and discusses ment of highly efficient systemic and targeted therapies has ongoing and future trials that address the possibility of a non- resulted in a marked improvement in pathologic complete operative approach in women with early-stage breast cancer. response (pCR) rates in specific breast cancer subtypes. As a . . result, breast surgeons are often
Current Breast Cancer Reports – Springer Journals
Published: Apr 22, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.